EUVIMEDEUVIMED entdecken
Open Access

Exploration of a Potential Desirability of Outcome Ranking Endpoint for Complicated Intra-Abdominal Infections Using 9 Registrational Trials for Antibacterial Drugs

Tori Kinamon, Ramya Gopinath, Ursula Waack, Mark Needles, Daniel Rubin, Deborah Collyar, Sarah B Doernberg, Scott Evans, Toshimitsu Hamasaki, Thomas L Holland, Jessica Howard-Anderson, Henry Chambers und 4 weitere

Clinical Infectious Diseases · 22.08.2023 · 77 (4) · 649-656

DOI: 10.1093/cid/ciad239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 19.04.2023. Verfasst von Tori Kinamon und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Intraabdominal Infections. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Desirability of outcome ranking (DOOR) is a novel approach to clinical trial design that incorporates safety and efficacy assessments into an ordinal ranking system to evaluate overall outcomes of clinical trial participants. Here, we derived and applied a disease-specific DOOR endpoint to registrational trials for complicated intra-abdominal infection (cIAI).

Methods

Initially, we applied an a priori DOOR prototype to electronic patient-level data from 9 phase 3 noninferiority trials for cIAI submitted to the US Food and Drug Administration between 2005 and 2019. We derived a cIAI-specific DOOR endpoint based on clinically meaningful events that trial participants experienced. Next, we applied the cIAI-specific DOOR endpoint to the same datasets and, for each trial, estimated the probability that a participant assigned to the study treatment would have a more desirable DOOR or component outcome than if assigned to the comparator.

Results

Three key findings informed the cIAI-specific DOOR endpoint: (1) a significant proportion of participants underwent additional surgical procedures related to their baseline infection; (2) infectious complications of cIAI were diverse; and (3) participants with worse outcomes experienced more infectious complications, more serious adverse events, and underwent more procedures. DOOR distributions between treatment arms were similar in all trials. DOOR probability estimates ranged from 47.4% to 50.3% and were not significantly different. Component analyses depicted risk-benefit assessments of study treatment versus comparator.

Conclusions

We designed and evaluated a potential DOOR endpoint for cIAI trials to further characterize overall clinical experiences of participants. Similar data-driven approaches can be utilized to create other infectious disease–specific DOOR endpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsIntraabdominal InfectionsHumansTreatment Outcome

Stichwörter der Autor:innen

DOORantimicrobial therapyclinical trialsendpointsintra-abdominal infection

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.
  • Department of Medicine, Duke University Medical Center, Durham, NC, USA.
  • Oak Ridge Institute for Science and Education, United States Department of Energy, Oak Ridge, TN, USA.
  • Patient Advocates in Research, Danville, CA, USA.
  • Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, CA, USA.
  • Biostatistics Center and Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia.

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • (NIH)
  • Antibacterial Resistance Leadership Group

Zitieren

APA

Kinamon, T., Gopinath, R., Waack, U., Needles, M., Rubin, D., Collyar, D., Doernberg, S. B., Evans, S., Hamasaki, T., Holland, T. L., Howard-Anderson, J., Chambers, H., Fowler, V. G., Nambiar, S., Kim, P., & Boucher, H. W. (2023). Exploration of a Potential Desirability of Outcome Ranking Endpoint for Complicated Intra-Abdominal Infections Using 9 Registrational Trials for Antibacterial Drugs. Clinical Infectious Diseases, 77(4), 649-656. https://doi.org/10.1093/cid/ciad239

Vancouver

Kinamon T, Gopinath R, Waack U, Needles M, Rubin D, Collyar D, et al. Exploration of a Potential Desirability of Outcome Ranking Endpoint for Complicated Intra-Abdominal Infections Using 9 Registrational Trials for Antibacterial Drugs. Clinical Infectious Diseases. 2023;77(4):649-656. doi:10.1093/cid/ciad239

BibTeX
@article{Kinamon2023,
  author = {Kinamon, Tori and Gopinath, Ramya and Waack, Ursula and Needles, Mark and Rubin, Daniel and Collyar, Deborah and Doernberg, Sarah B and Evans, Scott and Hamasaki, Toshimitsu and Holland, Thomas L and Howard-Anderson, Jessica and Chambers, Henry and Fowler, Vance G and Nambiar, Sumati and Kim, Peter and Boucher, Helen W},
  title = {Exploration of a Potential Desirability of Outcome Ranking Endpoint for Complicated Intra-Abdominal Infections Using 9 Registrational Trials for Antibacterial Drugs},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {77},
  number = {4},
  pages = {649--656},
  doi = {10.1093/cid/ciad239}
}
Kostenlos starten →